Syncom Formulations (India) Ltd (BSE: 524470) is a Indore, Madhya Pradesh-based company in the Pharmaceuticals industry. With a market capitalisation of ₹2,060 Cr, it ranks #1,226 by market cap among the 6,137 Indian listed companies on FinBizNet, and #21 of 63 in Pharmaceuticals. At ₹21.19 (as of 25 Oct 2026), the share price is 22.9% below its 52-week high of ₹27.49 and 107.5% above its 52-week low of ₹10.21. The share price is up 28.9% over one year and up 61.9% over three months.
| Current Price | ₹21.19 |
|---|---|
| Market Cap | ₹2,060 Cr |
| BSE Code | 524470 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 26.4 |
| Return on Equity | 20.19% |
| Return on Assets | 9.33% |
| 52-Week Range | ₹10.21 – ₹27.49 |
| 1-Year Price Change | +28.9% |
| 3-Month Price Change | +61.9% |
| Beta (1Y) | 0.98 |
| Dividend Yield | 0.47% |
| Headquarters | Indore, Madhya Pradesh |
| Website | www.syncomformulations.com |
| Revenue | ₹126 Cr |
|---|---|
| Net Profit | ₹25 Cr |
| Net Margin | 19.8% |
| EPS (Basic) | ₹0.26 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers its pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, liquids orals, and effervescent. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.
1. Pharmaceuticals Drugs & Formulations-This segment engages in manufacturing, selling, and dealing in pharmaceuticals and formulations. 2. Trading of Commodities-This segment engages in trading of commodities. 3. Renting of Property-This segment engages in the rental of properties. 4. Segment Adjustment-0
1. Pharmaceuticals Drugs & Formulations-99.1% 2. Trading of Commodities-0.2% 3. Renting of Property-0.7%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Syncom Formulations (India) Ltd | ₹2,060 Cr | 26.4 | 20.19% | ₹126 Cr | +28.9% |
Listed by market capitalisation. Ratios are shown for context only.
Syncom Formulations (India) Ltd is trading at ₹21.19, with a market capitalisation of ₹2,060 Cr.
Syncom Formulations (India) Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Syncom Formulations (India) Ltd has a P/E of 26.4 and a return on equity of 20.19%.
Syncom Formulations (India) Ltd is listed on the BSE under the scrip code 524470.
Syncom Formulations (India) Ltd's share price is up 28.9% over one year and up 61.9% over three months. Its 52-week range is ₹10.21 to ₹27.49.
In Q1 FY27, Syncom Formulations (India) Ltd reported revenue of ₹126 Cr and net profit of ₹25 Cr, with basic EPS of ₹0.26 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.